Deze website met internetadres http://www.pfizerpro.nl en alle hierop vermelde informatie is uitsluitend gericht op inwoners van Nederland.

Zoek

Menu

Close

Inloggen of registrerenUitloggenOnze geneesmiddelenZiektebeeldenOntdek meerOntdek meerEducatieMaterialenVideo'sPodcastOver PfizerOver PfizerNieuwsBlogsMedewerkers in beeldContactContactNeem gerust contact met ons opStel een vraagPfizer medische informatie

Onderaan de pagina kunt u bijwerkingen melden.

Home

Menu

Close

EfficacyEfficacy DataTrial DesignClinical RemissionEndoscopic ImprovementBio/JAKi Subgroups DataIsolated ProctitisSafetyAdverse eventsCardiac and ocular adverse eventsGetting StartedResourcesEventsMaterialsVideos
Velsipity is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost reponse, or were intolerant to either conventional therapy, or a biological agent.

VELSIPITY can offer your patients3:
  • An oral advanced UC therapy indicated for patients 16 years of age and older
  • Recommended monitoring for certain safety signals†
  • Same dose from the start—no titration required
 DISCOVER CLINICAL TRIAL DATA
  • Sustained, steroid-free remission3,4
  • Early onsert of symptomatic improvement by week 23
  • Higher rates of endoscopic improvement with VELSIPITY vs placebo3
  • An advanced therapy proven in patients with isolated proctitis in phase 3 randomized clinical trials6
 SEE THE DATALoading SEE THE SAFETY PROFILE
  • No increased risk of serious or opportunistic infections, including herpes zoster, vs placebo4
  • Well tolerated with mostly mild to moderate adverse events and discontinuation rates similar to placebo, supported by up to 2.5 years of clinical data4,7
  • The most common adverse reactions are lymphopenia (11%) and headache (7%)3
 SEE SAFETYLoading GET DOSING INFORMATION
  • The same dose right from the start— no titration3
  • Straightforward one-time testing3
  • Recommended monitoring for certain safety signals†
 GETTING STARTEDLoadingNo required scheduled monitoring outside of standard clinical assessments. Safety signals should be monitored during treatment and managed appropriately, as recommended in the Summary of Product Characteristics for VELSIPITY (etrasimod).References:Peyrin-Biroulet L, Van Assche G, Sturm A, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis. 2016;48(6):601-607.Dubinsky MC, Watanabe K, Molander P, et al; The Global UC Narrative Survey Panel. Ulcerative Colitis Narrative global survey findings: the impact of living with ulcerative colitis—patients’ and physicians’ view. Inflamm Bowel Dis. 2021;27(11):1747-1755. VELSIPITY (etrasimod) Summary of Product Characteristics. Brussels, Belgium: Pfizer Europe; February 2024.Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171. Sandborn WJ, Peyrin-Biroulet L, Eberhardson M et al: Efficacy and safety of VELISPITY administered by subcutaneous injection for the treatment of moderate to severe ulcerative colitis (ELEVATE UC). In two randomized double blind placebo-controlled phase 3 trials [abstract]. Presented at Digestive Disease Week Annual Meeting May 2023. Vermeire S., Hanauer S., Colombel JF et al.: Clinical remission achieved with VELISPITY as induction and maintenance therapy in moderate to severe ulcerative colitis (ELEVATE). In two randomized double-blind placebo-controlled phase III trials [abstract]. Presented at Digestive Disease Week Annual Meeting May 2023.VELISPITY administered by subcutaneous injection for the treatment of moderate to severe ulcerative colitis–patients’ and physicians’ views on efficacy (Abstract). Presented at Digestive Disease Week Annual Meeting May 2023.
PP-V1A-NLD-0012

Wilt u een bijwerking melden? Ga dan naar de 'Bijwerkingen melden' pagina en klik vervolgens op u van toepassing zijnde button.

PfizerPro AccountPfizerPro AccountU vindt informatie over geneesmiddelen, werkingsmechanismen, werkzame stoffen, doseringen en bijwerkingen die kunnen optreden. Zodat u nog beter in staat bent om uw patiënten te helpen.InloggenRegistrerenAccountUitloggen

De informatie die op deze website wordt aangeboden is uitsluitend bedoeld voor zorgverleners in Nederland. Bent u geen zorgverlener, maar patiënt of consument, ga dan naar www.pfizer.nl.

 

2025 Pfizer© Alle rechten voorbehouden.
 

PP-V1A-NLD-0012
U verlaat de website van Pfizer
Door op oké te klikken, verlaat u de website van Pfizer. De links naar websites buiten Pfizer worden u als service aangeboden. Pfizer heeft geen invloed op de inhoud van deze sites en is er niet voor verantwoordelijk.